AR and prostate cancer: The p38 MAPK inhibitor decreased cell proliferation under both normoxia and hypoxia in AR positive prostate cancer cells (VCaP, LNCaP, V16D), but not in AR-null prostate cancer cells (DU145, PC3) (Figure 1b).